Australian fertility provider Monash IVF Group has reported a significant financial downturn in its half-year results, with underlying profit after tax plummeting 34% to $10.4 million. The company attributes this decline to multiple factors, including market share losses and the financial impact of recent clinical controversies.
The financial report, released Thursday, reveals the fertility giant lost 2.5% of the Australian market share during the second half of 2025, dropping from 21.5% to 19% across all states except South Australia and the Northern Territory. Company documents acknowledge that ‘negative media impact on market share [was] most pronounced in jurisdictions with Monash IVF branding.’
This market erosion follows several high-profile incidents that damaged the company’s reputation. In April, the company apologized after a patient unknowingly gave birth to a stranger’s baby. Two months later, another incident emerged where Monash IVF incorrectly transferred the wrong embryo into a Melbourne patient.
Additionally, the company faced legal consequences for previous practices, agreeing to a $56 million settlement in August 2024 following a class action lawsuit. The litigation alleged the company destroyed embryos due to an inaccurate genetic screening program.
While the class action payout was accounted for previously, the company’s net finance costs increased by $1.1 million in the first half of this financial year, primarily due to borrowing required to cover the settlement.
Despite these challenges, Monash IVF reported that specialist staff have remained loyal to the organization. The company highlighted this retention as evidence of their team’s ‘commitment and alignment to Monash IVF’ despite the difficulties of the past year.
The financial results showed total revenue decreased 1.8% to $137.9 million, which the company attributed to ‘industry softness and domestic IVF market share loss,’ partially offset by price growth and international operations in Indonesia, Malaysia, and Singapore.
Newly appointed CEO and Managing Director Victoria Atkinson struck an optimistic tone in her statement: ‘I am pleased to commence as CEO and Managing Director of Monash IVF Group at an important time for the Company. Monash IVF has a strong clinical heritage, a dedicated team of specialists and embryologists, and a trusted national footprint.’
Atkinson identified her immediate focus would be on ‘clinical and operational excellence, supporting our clinicians and ensuring consistent, high quality patient experience across the network,’ while remaining ‘committed to executing our strategy and delivering sustainable value for shareholders.’
Since its establishment in 1991, Monash IVF has facilitated the birth of 71,296 babies, though recent events have clearly impacted both its clinical reputation and financial performance.